文献速递认知障碍与痴呆

在记忆门诊人群中应用ATN框架:ABIDE项目

Applying the ATN scheme in a memory clinic population: The ABIDE project.
PubMed 文献 · Neurology · 2019-10-09

该研究纳入305例记忆门诊患者,按淀粉样蛋白PET、脑脊液p-tau及内侧颞叶萎缩判定A/T/N阳性,分析ATN谱的基线特征与认知下降。结果发现A+T+N+比例随综合征严重度增加,阿尔茨海默病谱患者基线认知更差且MMSE下降更快。

要点

  • A+T+N+比例从SCD的1%升至MCI的14%和痴呆的35%。
  • A+T+N-和A+T+N+患者基线MMSE、记忆及视空间能力更差。
  • A+T+N-和A+T+N+的MMSE下降更快,主要见于非痴呆患者。

核心结论

  • ATN框架可识别不同生物标志物谱,但各谱基线特征重叠且认知下降模式各异。
  • ATN谱数量多且在痴呆与非痴呆患者中意义可能不同,给临床应用带来挑战。

研究设计与样本

  • 纳入305例记忆门诊患者,其中SCD 33%、MCI 19%、痴呆48%。
  • 以[18F]Florbetaben PET判定A,脑脊液p-tau判定T,内侧颞叶萎缩判定N。

主要发现

  • A+T+N+比例从SCD的1%增至MCI的14%和痴呆的35%,A-T-N-比例从48%降至19%和6%。
  • 相比A-T-N-,A+T+N-和A+T+N+患者年龄更大、APOE ε4比例更高、基线MMSE、记忆及视空间能力更低(均p<0.05)。
  • 非阿尔茨海默病谱A-T-N+和A-T+N+的白质高信号更严重且语言表现更差(均p<0.05)。
  • 线性混合模型显示A+T+N-和A+T+N+的MMSE随时间下降更快(分别p=0.059和p<0.001 vs A-T-N-),主要归因于非痴呆患者。

临床怎么用

  • 在记忆门诊中可依据ATN生物标志物谱识别阿尔茨海默病病理及认知下降风险较高的患者。
  • 需注意ATN谱在痴呆与非痴呆患者中可能具有不同临床意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To apply the ATN scheme to memory clinic patients, to assess whether it discriminates patient populations with specific features. METHODS: We included 305 memory clinic patients (33% subjective cognitive decline [SCD]: 60 ± 9 years, 61% M; 19% mild cognitive impairment [MCI]: 68 ± 9 years, 68% M; 48% dementia: 66 ± 10 years, 58% M) classified for positivity (±) of amyloid (A) ([18F]Florbetaben PET), tau (T) (CSF p-tau), and neurodegeneration (N) (medial temporal lobe atrophy). We assessed ATN profiles' demographic, clinical, and cognitive features at baseline, and cognitive decline over time. RESULTS: The proportion of A+T+N+ patients increased with syndrome severity (from 1% in SCD to 14% in MCI and 35% in dementia), while the opposite was true for A-T-N- (from 48% to 19% and 6%). Compared to A-T-N-, patients with the Alzheimer disease profiles (A+T+N- and A+T+N+) were older (both p < 0.05) and had a higher prevalence of APOE ε4 (both p < 0.05) and lower Mini-Mental State Examination (MMSE) (both p < 0.05), memory (both p < 0.05), and visuospatial abilities (both p < 0.05) at baseline. Non-Alzheimer profiles A-T-N+ and A-T+N+ showed more severe white matter hyperintensities (both p < 0.05) and worse language performance (both p < 0.05) than A-T-N-. A linear mixed model showed faster decline on MMSE over time in A+T+N- and A+T+N+ (p = 0.059 and p < 0.001 vs A-T-N-), attributable mainly to patients without dementia. CONCLUSIONS: The ATN scheme identified different biomarker profiles with overlapping baseline features and patterns of cognitive decline. The large number of profiles, which may have different implications in patients with vs without dementia, poses a challenge to the application of the ATN scheme.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Altomare D, de Wilde A, Ossenkoppele R, et al. Applying the ATN scheme in a memory clinic population: The ABIDE project. Neurology. 2019. PMID: 31597710. doi:10.1212/WNL.0000000000008361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。